Related Experiment Video
Updated: May 19, 2026

Electrophysiological Methods to Assess Peripheral Pain Block in an Anesthetized Rat
Published on: November 21, 2025
Pain inhibition by blocking leukocytic and neuronal opioid peptidases in peripheral inflamed tissue
Anja Schreiter1, Carmen Gore, Dominika Labuz
1Klinik für Anästhesiologie und operative Intensivmedizin, Freie Universität Berlin, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Abstract:
Inflammatory pain can be controlled by endogenous opioid peptides. Here we blocked the degradation of opioids in peripheral injured tissue to locally augment this physiological system. In rats with hindpaw inflammation, inhibitors of aminopeptidase N (APN; bestatin) or neutral endopeptidase (NEP; thiorphan), and a dual inhibitor, NH(2)-CH-Ph-P(O)(OH)CH(2)-CH-CH(2)Ph(p-Ph)-CONH-CH-CH(3)-COOH (P8B), were applied to injured paws. Combined bestatin (1.25-5 mg)/thiorphan (0.2-0.8 mg) or P8B (0.0625-1 mg) alone elevated mechanical nociceptive thresholds to 307 and 227% of vehicle-treated controls, respectively. This analgesia was abolished by antibodies to methionine-enkephalin, leucine-enkephalin, and dynorphin A 1-17, by peripherally restricted and by selective μ-, δ-, and κ-opioid receptor antagonists. Flow cytometry and photospectrometry revealed expression and metabolic activity of APN and NEP on macrophages, granulocytes, and sciatic nerves from inflamed tissue. Radioimmunoassays showed that inhibition of leukocytic APN and NEP by bestatin (5-500 μM)/thiorphan (1-100 μM) combinations or by P8B (1-100 μM) prevented the degradation of enkephalins. Blockade of neuronal peptidases by bestatin (0.5-10 mM)/thiorphan (0.1-5 mM) or by P8B (0.1-10 mM) additionally hindered dynorphin A 1-17 catabolism. Thus, leukocytes and peripheral nerves are important sources of APN and NEP in inflamed tissue, and their blockade promotes peripheral opioid analgesia.
Insights
Blocking opioid degradation in injured tissues enhances natural pain relief. Inhibiting aminopeptidase N (APN) and neutral endopeptidase (NEP) boosted peripheral opioid analgesia in rats with inflammation.
Area of Science:
- Pharmacology
- Neuroscience
- Pain Management
Background:
- Inflammatory pain is modulated by endogenous opioid peptides.
- Degradation of these opioids limits their therapeutic potential in peripheral tissues.
Purpose of the Study:
- To investigate the efficacy of blocking opioid degradation in peripheral injured tissue to augment endogenous opioid analgesia.
- To identify the sources and roles of peptidases in peripheral opioid metabolism during inflammation.
Main Methods:
- Administration of aminopeptidase N (APN) and neutral endopeptidase (NEP) inhibitors (bestatin, thiorphan, P8B) to inflamed rat hindpaws.
- Assessment of analgesia via mechanical nociceptive thresholds.
- Analysis of opioid receptor involvement using antibodies and receptor antagonists.
- Detection of APN and NEP expression and activity using flow cytometry and photospectrometry.
- Measurement of enkephalin and dynorphin A 1-17 degradation using radioimmunoassays.
Main Results:
- Combined APN/NEP inhibition or dual inhibitor P8B significantly elevated mechanical nociceptive thresholds.
- Analgesia was dependent on endogenous opioids (methionine-enkephalin, leucine-enkephalin, dynorphin A 1-17) and opioid receptors (μ, δ, κ).
- APN and NEP were expressed and metabolically active on leukocytes (macrophages, granulocytes) and sciatic nerves in inflamed tissue.
- Inhibition of these peptidases prevented opioid degradation and enhanced peripheral opioid analgesia.
Conclusions:
- Leukocytes and peripheral nerves are key sources of APN and NEP in inflamed tissues.
- Blockade of these peptidases effectively promotes peripheral opioid-mediated analgesia.
- Targeting peripheral opioid degradation represents a promising strategy for inflammatory pain management.
Related Concept Videos
Nociception
Analgesia and Pain Management
Local Anesthetics: Differential Sensitivity of Nerve Fibers
Pain
Acute Inflammation III: Local and Systemic Effects
Opioid Receptors: Overview
